{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T04:16:50Z","timestamp":1783397810758,"version":"3.54.6"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T00:00:00Z","timestamp":1775952000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100032738","name":"Brainlab","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006012","name":"Christian Doppler Research Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006012","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010132","name":"\u00d6sterreichische Nationalstiftung f\u00fcr Forschung, Technologie und Entwicklung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010132","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004320","name":"Philips","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004320","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011676","name":"Elekta","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011676","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005788","name":"Medizinische Universit\u00e4t Wien","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ctro.science","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical and Translational Radiation Oncology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ctro.2026.101169","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T15:56:41Z","timestamp":1776959801000},"page":"101169","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Prospective evaluation of acute side effects profiles in moderately hypofractionated whole-pelvic radiotherapy for prostate cancer"],"prefix":"10.1016","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-4089-5144","authenticated-orcid":false,"given":"Leo","family":"Andexlinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4031-1711","authenticated-orcid":false,"given":"Barbara","family":"Kn\u00e4usl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9813-0919","authenticated-orcid":false,"given":"Andreas","family":"Renner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1525-6423","authenticated-orcid":false,"given":"Maximilian","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8327-3877","authenticated-orcid":false,"given":"Dietmar","family":"Georg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9972-6690","authenticated-orcid":false,"given":"Joachim","family":"Widder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2689-341X","authenticated-orcid":false,"given":"Gregor","family":"Goldner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7461-3956","authenticated-orcid":false,"given":"Gerd","family":"Heilemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctro.2026.101169_b1","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2024.102700","article-title":"Prostate cancer incidence rates, trends, and treatment related to prostate-specific antigen screening recommendations in the United States","volume":"93","author":"Merrill","year":"2024","journal-title":"Cancer Epidemiol"},{"issue":"17","key":"10.1016\/j.ctro.2026.101169_b2","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1200\/JCO.2017.72.7016","article-title":"Hypofractionated Radiotherapy for Prostate Cancer: Further Evidence to Tip the Scales","volume":"35","author":"Yu","year":"2017","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ctro.2026.101169_b3","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ctro.2026.101169_b4","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.euo.2021.07.005","article-title":"Impact of Hypofractionated Radiotherapy on Patient-reported Outcomes in Prostate Cancer: Results up to 5 yr in the CHHiP trial (CRUK\/06\/016)","volume":"4","author":"Staffurth","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.ctro.2026.101169_b5","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S1470-2045(16)30070-5","article-title":"Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial","volume":"17","author":"Incrocci","year":"2016","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ctro.2026.101169_b6","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.ijrobp.2021.10.139","article-title":"Patient-Reported Outcomes in the Acute Phase of the Randomized Hypofractionated Irradiation for Prostate Cancer (HYPRO) Trial","volume":"112","author":"Sinzabakira","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"20","key":"10.1016\/j.ctro.2026.101169_b7","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1200\/JCO.2016.67.0448","article-title":"Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer","volume":"34","author":"Lee","year":"2016","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.ctro.2026.101169_b8","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1200\/JCO.23.02445","article-title":"Long-Term Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Noninferiority Study Comparing Two Fractionation Schedules in Patients With Low-Risk Prostate Cancer","volume":"42","author":"Lee","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctro.2026.101169_b9","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.radonc.2019.12.006","article-title":"Late toxicity and quality of life with prostate only or whole pelvic radiation therapy in high risk prostate cancer (POP-RT): A randomised trial","volume":"145","author":"Murthy","year":"2020","journal-title":"Radiother Oncol"},{"issue":"3","key":"10.1016\/j.ctro.2026.101169_b10","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ijrobp.2018.10.003","article-title":"Toxicity and Patient-Reported Outcomes of a Phase 2 Randomized Trial of Prostate and Pelvic Lymph Node Versus Prostate only Radiotherapy in Advanced Localised Prostate Cancer (PIVOTAL)","volume":"103","author":"Dearnaley","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2026.101169_b11","doi-asserted-by":"crossref","first-page":"S673","DOI":"10.1016\/j.annonc.2021.08.1159","article-title":"646TiP A randomized phase III, factorial design, of cabazitaxel and pelvic radiotherapy in patients with localized prostate cancer and high-risk features of relapse: The PEACE 2 trial from Unicancer","volume":"32","author":"Blanchard","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctro.2026.101169_b12","first-page":"22","article-title":"PIVOTALboost: A phase III randomised controlled trial of prostate and pelvis versus prostate alone radiotherapy with or without prostate boost (CRUK\/16\/018)","volume":"25","author":"Syndikus","year":"2020","journal-title":"Clin Transl Radiat Oncol"},{"issue":"1","key":"10.1016\/j.ctro.2026.101169_b13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/PPO.0b013e3182467419","article-title":"Improvement in prostate cancer survival over time: A 20-year analysis","volume":"18","author":"Kim","year":"2012","journal-title":"Cancer J"},{"issue":"7","key":"10.1016\/j.ctro.2026.101169_b14","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.3390\/cancers14071670","article-title":"A Comparison between Patient- and Physician-Reported Late Radiation Toxicity in Long-Term Prostate Cancer Survivors","volume":"14","author":"Nuijens","year":"2022","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.ctro.2026.101169_b15","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/0360-3016(95)00060-C","article-title":"Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European organization for research and treatment of cancer (EORTC)","volume":"31","author":"Cox","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2026.101169_b16","article-title":"On the sensitivity of PROMs during breast radiotherapy","volume":"39","author":"Heilemann","year":"2023","journal-title":"Clin Transl Radiat Oncol"},{"issue":"5","key":"10.1016\/j.ctro.2026.101169_b17","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00066-018-1395-y","article-title":"Patient- versus physician-reported outcomes in prostate cancer patients receiving hypofractionated radiotherapy within a randomized controlled trial","volume":"195","author":"Rammant","year":"2019","journal-title":"Strahlenther Onkol"},{"issue":"1","key":"10.1016\/j.ctro.2026.101169_b18","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0360-3016(94)90138-4","article-title":"Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and gleason score in men with clinically localized prostate cancer","volume":"28","author":"Roach","year":"1994","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2026.101169_b19","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110427","article-title":"Automation of ePROMs in radiation oncology and its impact on patient response and bias","volume":"199","author":"Heilemann","year":"2024","journal-title":"Radiother Oncol"},{"issue":"9","key":"10.1016\/j.ctro.2026.101169_b20","doi-asserted-by":"crossref","first-page":"dju244","DOI":"10.1093\/jnci\/dju244","article-title":"Development of the national cancer institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)","volume":"106","author":"Basch","year":"2014","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.ctro.2026.101169_b21","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1177\/17407745241286065","article-title":"Statistical properties of items and summary scores from the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE\u00ae ) in a diverse cancer sample","volume":"22","author":"Mead-Harvey","year":"2025","journal-title":"Clin Trials"},{"issue":"21","key":"10.1016\/j.ctro.2026.101169_b22","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.3390\/cancers17213459","article-title":"Psychometric Properties and Interpretability of PRO-CTCAE\u00ae Average Composite Scores as a Summary Metric of Symptomatic Adverse Event Burden","volume":"17","author":"Lee","year":"2025","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.ctro.2026.101169_b23","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.radonc.2012.05.007","article-title":"Late gastrointestinal and urogenital side-effects after radiotherapy \u2013 Incidence and prevalence. Subgroup-analysis within the prospective Austrian\u2013German phase II multicenter trial for localized prostate cancer","volume":"104","author":"Schmid","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2026.101169_b24","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2022.11.015","article-title":"Comparing symptom reporting by prostate cancer patients and healthcare professionals in the international multicentre REQUITE study","volume":"178","author":"Heumann","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2026.101169_b25","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1168219","article-title":"A comparison of machine learning models for predicting urinary incontinence in men with localized prostate cancer","volume":"13","author":"Hasannejadasl","year":"2023","journal-title":"Front Oncol"}],"container-title":["Clinical and Translational Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630826000649?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630826000649?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T03:42:16Z","timestamp":1783395736000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405630826000649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":25,"alternative-id":["S2405630826000649"],"URL":"https:\/\/doi.org\/10.1016\/j.ctro.2026.101169","relation":{},"ISSN":["2405-6308"],"issn-type":[{"value":"2405-6308","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prospective evaluation of acute side effects profiles in moderately hypofractionated whole-pelvic radiotherapy for prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical and Translational Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctro.2026.101169","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101169"}}